Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Top Story

Half empty glass

BC Staff
March 30, 2000 8:00 AM UTC

Regeneron (REGN) left more than $120 million on the table in its Thursday follow-on. The company, which has compounds in development for obesity, rheumatoid arthritis and other diseases, raised $77.4 million through the sale of 2.6 million shares at $29.75. The sum is a far cry from the $201.2 million REGN could have raised had it sold the proposed 4 million shares at its price prior to filing of $50.297. The deal was underwritten by Merrill Lynch; Lehman Brothers; J.P. Morgan; and Robertson Stephens. REGN was down $1 to $28.688 on Thursday.

Pharmacogenomics play Visible Genetics (VGIN) also experienced the softening follow-on market. VGIN raised $76 million through the sale of 2 million shares at $38 underwritten by Robertson Stephens; PaineWebber; Warburg Dillon Read; and Roth Capital Partners. Had VGIN sold the shares at its $83.50 price prior to filing on March 13, the company would have raised $167 million. VGIN was down $3.813 to $36.375 on Thursday. ...